智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年12月31日，该公司斥资113.24万港元回购10万 股股份，每股回购价格为11.17-11.46港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年12月31日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 ...

本文源自：格隆汇 格隆汇12月30日丨歌礼制药-B(01672.HK)发布公告，2025年12月30日耗资115.3万港元回购10万股，回 购价格每股11.41-11.64港元。 ...

Group 1 - The company, Gilead Sciences-B (01672), announced a share buyback plan, intending to repurchase 100,000 shares at a cost of HKD 1.1529 million [1] - The buyback is scheduled to be executed by December 30, 2025 [1] - This move indicates the company's strategy to enhance shareholder value through capital return initiatives [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年12月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前 ...

Group 1: Market Overview - The industrial bond market has seen a total issuance of 7,440 bonds, amounting to 8.60 trillion yuan, covering 29 primary industries, with 16 industries exceeding 100 billion yuan in issuance for the year, notably including public utilities, non-bank financials, and transportation [1] - The A-share market has continued to experience a volatile upward trend, with significant increases in weekly financing and a net inflow of 36.34 billion yuan into stock ETFs, indicating a positive funding environment [2] Group 2: Real Estate Sector - As of December 28, 2025, new home transactions in 20 cities totaled 774,000 units, reflecting a decrease of 16.5%, with notable declines in Beijing (21%), Shanghai (5%), and Shenzhen (38%) [3] - The secondary housing market in 10 cities recorded 756,000 transactions, a slight decrease of 0.7%, with Beijing showing a minor decline of 1% and Shanghai experiencing a 6% increase [3] Group 3: Pharmaceutical Industry - The oral semaglutide for weight loss received FDA approval, with significant clinical data from related companies indicating a shift from research validation to commercial confirmation, suggesting investment opportunities in leading firms like Goliath Pharmaceuticals and Hengrui Medicine [4] Group 4: Metals and Materials Sector - Lithium prices have reached approximately 112,000 yuan per ton, with recommendations to focus on companies with cost advantages and resource expansion potential, such as Salt Lake Co. and Tianqi Lithium [5] - Cobalt prices have increased across multiple varieties, with a recommendation to monitor Huayou Cobalt [5] - Prices for praseodymium and neodymium oxides are at a 19-month high, indicating potential investment opportunities in companies like Northern Rare Earth and Shenghe Resources [5]

Market Overview - The A-share market continues to experience a震荡上涨, with major indices showing recovery in both volume and liquidity. Weekly financing increased significantly, with stock ETFs seeing a net inflow of 36.34 billion yuan, indicating positive market sentiment following the Central Economic Work Conference in December [5][6]. Industry Insights - The copper price outlook remains positive, supported by the National Development and Reform Commission's emphasis on optimizing traditional industries, including copper smelting. Despite a decrease in cable companies' operating rates, the supply-demand dynamics for copper are expected to remain tight into 2026, favoring price increases [5]. - The steel sector is facing a high inventory level for hot-rolled coils, the highest in five years. The Central Economic Work Conference has reiterated the need for controlling crude steel production, which may lead to a more balanced supply and improved profitability for the steel sector in the long term [6]. Utilities Sector - The annual long-term contract bidding results in Guangdong met expectations, with the comprehensive on-grid electricity price remaining stable. Additionally, the capacity subsidy in Shanghai has increased to 165 yuan per kilowatt for 2026. As of November, the total electricity consumption increased by 6.2% year-on-year, and the cumulative installed power generation capacity rose by 17.1% year-on-year [8]. Pharmaceutical Sector - The approval of oral semaglutide for weight loss by the FDA is expected to catalyze industry growth. Recent clinical data from Structure and Gilead Pharmaceuticals has shown promising results, and collaborations between Pfizer and Fosun Pharma for oral small molecule weight loss drugs are underway. Furthermore, Shiyao Innovation has announced a platform integration for its GLP-1 business [8].

Core Viewpoint - The oral weight loss drug sector is entering a critical commercialization phase, with significant regulatory approvals and partnerships indicating strong market potential and demand for innovative treatments [4][5][6]. Group 1: Recent Developments in Oral Weight Loss Drugs - On December 23, 2025, the FDA approved Novo Nordisk's oral semaglutide for chronic weight management, marking a significant milestone for oral GLP-1 peptides [4]. - Eli Lilly's management anticipates that the oral small molecule weight loss drug orforglipron will likely receive approval by March 2026, potentially becoming the second approved oral weight loss medication [4]. - Recent data releases include Structure's report on aleniglipron, which showed a 11.3% weight loss in the 120mg dose group and 15.3% in the 240mg dose group after 36 weeks [4]. Group 2: Industry Partnerships and Strategic Moves - On December 9, 2025, Pfizer announced an exclusive collaboration with YaoPharma for the oral small molecule GLP-1R agonist YP05002, involving a $150 million upfront payment and up to $1.935 billion in milestones, indicating strong interest from multinational pharmaceutical companies in oral weight loss products [5]. - Shijiazhuang Pharmaceutical Innovation announced the establishment of a joint venture focused on innovative metabolic drug development, highlighting the recognition of the significant value in GLP-1 related metabolic disease medications [6]. Group 3: Market Trends and Valuation Recovery - The pharmaceutical and biotechnology sector has seen a recovery in valuation, with the PE ratio stabilizing and increasing since Q1 2025, driven by macroeconomic conditions and supportive policies for innovative drugs [7]. - The global trend of returning to a rate-cutting environment, alongside increasing healthcare spending due to aging populations, is expected to expand the global demand for pharmaceuticals, particularly benefiting China's pharmaceutical industry [8]. Group 4: Investment Themes in Innovation - The investment focus is categorized into three phases: "0→1" for breakthrough technologies in innovative drugs, "1→10" for clinical validation of high-quality domestic innovative drugs, and "10→100" for leveraging China's efficiency in the pharmaceutical supply chain [9]. - The acceleration of business development (BD) for innovative drugs and the rise of high-end medical devices and consumables are seen as promising investment opportunities [9].

格隆汇12月29日丨歌礼制药-B(01672.HK)发布公告，2025年12月29日耗资248.3万港元回购20万股，回 购价格每股12.17-12.66港元。 ...

Core Viewpoint - The company, Gilead Sciences-B (01672), announced a share buyback program, indicating confidence in its financial position and future prospects [1] Group 1: Share Buyback Details - The company plans to repurchase 200,000 shares at a total cost of HKD 2.4829 million [1] - The buyback price per share ranges from HKD 12.17 to HKD 12.66 [1]